Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

NCT03924466 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Carcinoma
Locally Advanced Breast Cancer
Cancer of Pancreas
Solid Tumor With Intermediate or High HER2 Expression
Salivary Gland Cancer
Gastric Cancer
Endometrial Cancer
Uterine Cancer
Non Small Cell Lung Cancer
Biliary Tract Cancer
Cholangiocarcinoma
Colorectal Cancer
Urothelial Carcinoma
Prostate Cancer

Interventions

DRUG: 68GaNOTA-Anti-HER2 VHH1

Sponsor

Universitair Ziekenhuis Brussel

Collaborators

[object Object]
[object Object]